Dr. O'Donnell Compares Checkpoint Inhibitors in Bladder Cancer

Peter O'Donnell, MD
Published: Thursday, Oct 11, 2018



Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, compares checkpoint inhibitors in the treatment of patients with bladder cancer.

Currently, immunotherapy agents can only be compared by extrapolation because there have not yet been head-to-head clinical trials in this space, O’Donnell says. In phase III clinical trials looking at the platinum-refractory setting, pembrolizumab (Keytruda) has shown a survival advantage against taxane-based chemotherapy. In the same comparison, atezolizumab (Tecentriq) did not show such benefit. As a result, O’Donnell says he finds himself using pembrolizumab because of its Level 1 designation in the platinum-refractory space. He concludes that more survival data are needed to fully distinguish between the available immunotherapies.

Both atezolizumab, a PD-L1 inhibitor, and pembrolizumab, a PD-1 inhibitor, are FDA approved for the frontline treatment of patients with metastatic urothelial carcinoma. The approvals were announced following the results of the IMvigor210 and KEYNOTE-052 studies.
SELECTED
LANGUAGE


Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, compares checkpoint inhibitors in the treatment of patients with bladder cancer.

Currently, immunotherapy agents can only be compared by extrapolation because there have not yet been head-to-head clinical trials in this space, O’Donnell says. In phase III clinical trials looking at the platinum-refractory setting, pembrolizumab (Keytruda) has shown a survival advantage against taxane-based chemotherapy. In the same comparison, atezolizumab (Tecentriq) did not show such benefit. As a result, O’Donnell says he finds himself using pembrolizumab because of its Level 1 designation in the platinum-refractory space. He concludes that more survival data are needed to fully distinguish between the available immunotherapies.

Both atezolizumab, a PD-L1 inhibitor, and pembrolizumab, a PD-1 inhibitor, are FDA approved for the frontline treatment of patients with metastatic urothelial carcinoma. The approvals were announced following the results of the IMvigor210 and KEYNOTE-052 studies.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x